Skip to main content

Table 1 Adequate organ function laboratory values

From: A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

System

Laboratory value

Hematological

 Absolute neutrophil count

≥1500/mcL

 Platelets

≥100,000/mcL

 Hemoglobin

≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment)

Renal

 Serum creatinine OR

Measured or calculateda creatinine clearance

≤1.5 X upper limit of normal (ULN) OR

≥60 mL/min for subject with creatinine levels >1.5 X institutional ULN

Hepatic

 Serum total bilirubin

≤1.5 X ULN OR

 

Direct bilirubin ≤ULN for subjects with total bilirubin levels >1.5 ULN

 AST (SGOT) and ALT (SGPT)

≤2.5 X ULN OR

≤5 X ULN for subjects with liver metastases

 Albumin

≥25 g/L

Coagulation

 International normalized ratio (INR) or prothrombin time (PT)

Activated partial thromboplastin time (aPTT)

≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

  1. aCreatinine clearance should be calculated per institutional standard